{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:41:12Z","timestamp":1792762872691,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess caregiver burden, health-related quality of life, and work productivity among primary caregivers of individuals with cystic fibrosis (CF) in Brazil, comparing caregivers of patients using elexacaftor\/tezacaftor\/ivacaftor (ETI) with those of non-users, and analyzing differences according to the age group of the care recipient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study was conducted between September and November 2025 using an online questionnaire. Eligible participants were primary caregivers of individuals with CF living in Brazil. Collected data included sociodemographics, CFTR modulator use, caregiving time, and out-of-pocket health-related expenses. Validated instruments included the 12-item Zarit Burden Interview (ZBI-12), the EQ-5D-3L (utility index and Visual Analogue Scale), and the Work Productivity and Activity Impairment Questionnaire for Caregivers (WPAI: CG). Descriptive analyses and group comparisons were stratified by ETI use and age group of the care recipient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 174 caregivers from all Brazilian regions participated; 90.2% were mothers, with a median age of 35 years (IQR: 28\u201345). The individuals receiving care had a median age of 11 years (IQR: 7\u201314) among modulator users and 3 years (IQR: 1\u20137) among non-users, and 44.8% used CFTR modulators. Caregivers of non-modulator users dedicated significantly more time to daily caregiving (300\u00a0min [IQR: 180\u2013300] vs. 180\u00a0min [IQR: 90\u2013240];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002) and reported more frequent consultations (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). ZBI-12 scores were higher in the no-modulator group (20.0 [IQR: 16.0\u201325.2] vs. 15.5 [IQR: 11.2\u201323.0];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006), with the greatest difference observed among caregivers of children under 5 years (20.0 vs. 14.0;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), a group currently without access to modulators through the public health system. EQ-VAS was lower in the no-modulator group (65.0 [IQR: 50.0\u201380.0] vs. 70.0 [IQR: 50.0\u201380.0];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041). Absenteeism (15.8% [IQR: 0.0\u201328.6] vs. 0.0% [IQR: 0.0\u201316.4];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.034), presenteeism (50.0% [IQR: 5.0\u201360.0] vs. 20.0% [IQR: 0.0\u201350.0];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.048), and activity impairment (50.0% [IQR: 22.5\u201370.0] vs. 30.0% [IQR: 0.0\u201360.0];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011) were significantly higher among caregivers without modulator access.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Use of CFTR modulators was associated with lower caregiver burden, better health perception, and reduced work productivity loss.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04514-z","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:35:24Z","timestamp":1784799324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of CFTR modulators on caregiver burden in cystic fibrosis: a cross-sectional study in Brazil"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9528-9374","authenticated-orcid":false,"given":"Ver\u00f4nica Del Gragnano Stasiak Bedna","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vin\u00edcius Bednarczuk","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marise Basso","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilis Dallarmi","family":"Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"10290","key":"4514_CR1","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","volume":"397","author":"M Shteinberg","year":"2021","unstructured":"Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021;397(10290):2195\u2013211. https:\/\/doi.org\/10.1016\/S0140-6736(20)32542-3.","journal-title":"Lancet"},{"issue":"1","key":"4514_CR2","doi-asserted-by":"publisher","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","volume":"1","author":"F Ratjen","year":"2015","unstructured":"Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat Rev Dis Primer. 2015;1(1):15010. https:\/\/doi.org\/10.1038\/nrdp.2015.10.","journal-title":"Nat Rev Dis Primer"},{"issue":"10059","key":"4514_CR3","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"JS Elborn","year":"2016","unstructured":"Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(16)00576-6.","journal-title":"Lancet"},{"key":"4514_CR4","doi-asserted-by":"publisher","unstructured":"Morrison CB, Markovetz MR, Ehre C. Mucus, mucins, and cystic fibrosis. Pediatr Pulmonol. 2019;54(S3). https:\/\/doi.org\/10.1002\/ppul.24530.","DOI":"10.1002\/ppul.24530"},{"issue":"1","key":"4514_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev-med-112717-094536","volume":"70","author":"MM Rey","year":"2019","unstructured":"Rey MM, Bonk MP, Hadjiliadis D. Cystic Fibrosis: Emerging Understanding and Therapies. Annu Rev Med. 2019;70(1):197\u2013210. https:\/\/doi.org\/10.1146\/annurev-med-112717-094536.","journal-title":"Annu Rev Med"},{"issue":"2","key":"4514_CR6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jcf.2017.11.019","volume":"17","author":"RH Keogh","year":"2018","unstructured":"Keogh RH, Szczesniak R, Taylor-Robinson D, Bilton D. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data. J Cyst Fibros. 2018;17(2):218\u201327. https:\/\/doi.org\/10.1016\/j.jcf.2017.11.019.","journal-title":"J Cyst Fibros"},{"issue":"10","key":"4514_CR7","doi-asserted-by":"publisher","first-page":"e00049719","DOI":"10.1590\/0102-311x00049719","volume":"36","author":"LMZ Maciel","year":"2020","unstructured":"Maciel LMZ, Magalh\u00e3es PKR, Ciampo IRLD, et al. The first five-year evaluation of cystic fibrosis neonatal screening program in S\u00e3o Paulo State, Brazil. Cad Sa\u00fade P\u00fablica. 2020;36(10):e00049719. https:\/\/doi.org\/10.1590\/0102-311x00049719.","journal-title":"Cad Sa\u00fade P\u00fablica"},{"issue":"3","key":"4514_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1590\/s1806-37562017000000065","volume":"43","author":"RA Athanazio","year":"2017","unstructured":"Athanazio RA, Silva Filho LVRFD, Vergara AA, et al. Brazilian guidelines for the diagnosis and treatment of cystic fibrosis. J Bras Pneumol. 2017;43(3):219\u201345. https:\/\/doi.org\/10.1590\/s1806-37562017000000065.","journal-title":"J Bras Pneumol"},{"key":"4514_CR9","unstructured":"Grupo Brasileiro de Estudos em Fibrose C\u00edstica. Brazilian Cystic Fibrosis Registry 2023 (REBRAFC). S\u00e3o Paulo: GBEFC; 2023. Available from: https:\/\/portalgbefc.org.br\/ckfinder\/userfiles\/files\/REBRAFC_2023.pdf."},{"key":"4514_CR10","doi-asserted-by":"publisher","unstructured":"Jaques R, Shakeel A, Hoyle C. Novel therapeutic approaches for the management of cystic fibrosis. Multidiscip Respir Med. 2020;15. https:\/\/doi.org\/10.4081\/mrm.2020.690.","DOI":"10.4081\/mrm.2020.690"},{"issue":"1","key":"4514_CR11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","volume":"14","author":"L Allen","year":"2023","unstructured":"Allen L, Allen L, Carr SB, et al. Future therapies for cystic fibrosis. Nat Commun. 2023;14(1):693. https:\/\/doi.org\/10.1038\/s41467-023-36244-2.","journal-title":"Nat Commun"},{"issue":"1","key":"4514_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12967-017-1193-9","volume":"15","author":"MM Rafeeq","year":"2017","unstructured":"Rafeeq MM, Murad HAS. Cystic fibrosis: current therapeutic targets and future approaches. J Transl Med. 2017;15(1):84. https:\/\/doi.org\/10.1186\/s12967-017-1193-9.","journal-title":"J Transl Med"},{"key":"4514_CR13","doi-asserted-by":"publisher","first-page":"175346662210864","DOI":"10.1177\/17534666221086416","volume":"16","author":"C Daly","year":"2022","unstructured":"Daly C, Ruane P, O\u2019Reilly K, Longworth L, Vega-Hernandez G. Caregiver burden in cystic fibrosis: a systematic literature review. Ther Adv Respir Dis. 2022;16:17534666221086416. https:\/\/doi.org\/10.1177\/17534666221086416.","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"4514_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jcf.2017.08.016","volume":"17","author":"C Fitzgerald","year":"2018","unstructured":"Fitzgerald C, George S, Somerville R, Linnane B, Fitzpatrick P. Caregiver burden of parents of young children with cystic fibrosis. J Cyst Fibros. 2018;17(1):125\u201331. https:\/\/doi.org\/10.1016\/j.jcf.2017.08.016.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"4514_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/jcm10010023","volume":"10","author":"R Dagenais","year":"2020","unstructured":"Dagenais R, Su V, Quon B. Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review. J Clin Med. 2020;10(1):23. https:\/\/doi.org\/10.3390\/jcm10010023.","journal-title":"J Clin Med"},{"issue":"1","key":"4514_CR16","doi-asserted-by":"publisher","first-page":"7234","DOI":"10.1038\/s41598-019-43652-2","volume":"9","author":"ARR Habib","year":"2019","unstructured":"Habib ARR, Kajbafzadeh M, Desai S, Yang CL, Skolnik K, Quon BS. A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis. Sci Rep. 2019;9(1):7234. https:\/\/doi.org\/10.1038\/s41598-019-43652-2.","journal-title":"Sci Rep"},{"key":"4514_CR17","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","volume":"10","author":"MCFTR Lopes-Pacheco","year":"2020","unstructured":"Lopes-Pacheco MCFTR, Modulators. The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Front Pharmacol. 2020;10:1662. https:\/\/doi.org\/10.3389\/fphar.2019.01662.","journal-title":"Front Pharmacol"},{"issue":"8","key":"4514_CR18","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/17460441.2021.1912732","volume":"16","author":"M Lopes-Pacheco","year":"2021","unstructured":"Lopes-Pacheco M, Pedemonte N, Veit G. Discovery of CFTR modulators for the treatment of cystic fibrosis. Expert Opin Drug Discov. 2021;16(8):897\u2013913. https:\/\/doi.org\/10.1080\/17460441.2021.1912732.","journal-title":"Expert Opin Drug Discov"},{"issue":"3","key":"4514_CR19","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/ph16030410","volume":"16","author":"M Bacalhau","year":"2023","unstructured":"Bacalhau M, Camargo M, Magalh\u00e3es-Ghiotto GAV, Drumond S, Castelletti CHM, Lopes-Pacheco M. Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis. Pharmaceuticals. 2023;16(3):410. https:\/\/doi.org\/10.3390\/ph16030410.","journal-title":"Pharmaceuticals"},{"issue":"16","key":"4514_CR20","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.3390\/healthcare13161996","volume":"13","author":"VSB Oliveira","year":"2025","unstructured":"Oliveira VSB, Amaral MB, Camargo M, Lopes-Pacheco M. Building lay society knowledge and education for health technology assessment and policy engagement: case of CFTR modulator access in Brazil. Healthc (Basel). 2025;13(16):1996. https:\/\/doi.org\/10.3390\/healthcare13161996.","journal-title":"Healthc (Basel)"},{"issue":"1","key":"4514_CR21","doi-asserted-by":"publisher","first-page":"22678","DOI":"10.1038\/s41598-025-08866-7","volume":"15","author":"J Domaradzki","year":"2025","unstructured":"Domaradzki J, Jabkowski P, Walkowiak D. Rare disease, common struggles: quality of life, caregiver burden and financial wellbeing of family caregivers in Poland. Sci Rep. 2025;15(1):22678. https:\/\/doi.org\/10.1038\/s41598-025-08866-7.","journal-title":"Sci Rep"},{"issue":"2","key":"4514_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.30994\/jnp.v8i2.509","volume":"8","author":"N Nirmalasari","year":"2025","unstructured":"Nirmalasari N, Sari IWW. Caregiver burden on caregiver with chronic disease. J Nurs Pract. 2025;8(2):437\u201347. https:\/\/doi.org\/10.30994\/jnp.v8i2.509.","journal-title":"J Nurs Pract"},{"issue":"10","key":"4514_CR23","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1007\/s11136-025-04021-x","volume":"34","author":"S Chowdhury","year":"2025","unstructured":"Chowdhury S, Cubi-Molla P, Mott D. Effect of caregiver burden on the quality of life of informal caregivers of people with cystic fibrosis in the United Kingdom: a cross-sectional study. Qual Life Res. 2025;34(10):2995\u20133006. https:\/\/doi.org\/10.1007\/s11136-025-04021-x.","journal-title":"Qual Life Res"},{"issue":"1","key":"4514_CR24","doi-asserted-by":"publisher","first-page":"e20220306","DOI":"10.36416\/1806-3756\/e20220306","volume":"49","author":"EFA Procianoy","year":"2023","unstructured":"Procianoy EFA, Ludwig Neto N, Ribeiro AF. Patient care in cystic fibrosis centers: a real-world analysis in Brazil. J Bras Pneumol. 2023;49(1):e20220306. https:\/\/doi.org\/10.36416\/1806-3756\/e20220306.","journal-title":"J Bras Pneumol"},{"issue":"5","key":"4514_CR25","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1590\/1413-81232018235.18222016","volume":"23","author":"SP Alves","year":"2018","unstructured":"Alves SP, Bueno D. O perfil dos cuidadores de pacientes pedi\u00e1tricos com fibrose c\u00edstica. Ci\u00eanc Sa\u00fade Coletiva. 2018;23(5):1451\u20137. https:\/\/doi.org\/10.1590\/1413-81232018235.18222016.","journal-title":"Ci\u00eanc Sa\u00fade Coletiva"},{"key":"4514_CR26","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/j.pedn.2025.02.007","volume":"81","author":"ZH Chirani","year":"2025","unstructured":"Chirani ZH, Pouralizadeh M, Yaghobi Y, Kazemnejad Leili E. Relationship of caregiving burden and adaptive behaviors in mothers of children with chronic diseases. J Pediatr Nurs. 2025;81:e113\u201320. https:\/\/doi.org\/10.1016\/j.pedn.2025.02.007.","journal-title":"J Pediatr Nurs"},{"issue":"4","key":"4514_CR27","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1590\/0104-1169.0196.2613","volume":"23","author":"EC Macedo","year":"2015","unstructured":"Macedo EC, Silva LRD, Paiva MS, Ramos MNP. Burden and quality of life of mothers of children and adolescents with chronic illnesses: an integrative review. Rev Lat Am Enfermagem. 2015;23(4):769\u201377. https:\/\/doi.org\/10.1590\/0104-1169.0196.2613.","journal-title":"Rev Lat Am Enfermagem"},{"issue":"3","key":"4514_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.21765\/pprjournal.1522203","volume":"12","author":"E Karakaya","year":"2024","unstructured":"Karakaya E, Kam\u0131\u015fl\u0131 S. Care Burden and Psychological Resilience of Mothers Accompanying Their Children with Chronic Illnesses Hospitalized in Pediatric Wards. Pediatr Pract Res. 2024;12(3):66\u201372. https:\/\/doi.org\/10.21765\/pprjournal.1522203.","journal-title":"Pediatr Pract Res"},{"key":"4514_CR29","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas da Fibrose C\u00edstica. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2024. Available from: https:\/\/www.gov.br\/conitec\/pt-br\/midias\/relatorios\/2024\/RRPCDTdeFibroseCstica_Final.pdf\/view."},{"issue":"17\u201318","key":"4514_CR30","doi-asserted-by":"publisher","first-page":"6485","DOI":"10.1111\/jocn.16672","volume":"32","author":"KK Shattnawi","year":"2023","unstructured":"Shattnawi KK, Al Ali N, Almanasreh AA, Al-Motlaq MA. Caregiver burden among parents of children with chronic diseases: A cross\u2010sectional study. J Clin Nurs. 2023;32(17\u201318):6485\u201393. https:\/\/doi.org\/10.1111\/jocn.16672.","journal-title":"J Clin Nurs"},{"issue":"6","key":"4514_CR31","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1017\/S1478951517000918","volume":"16","author":"A Wojtaszczyk","year":"2018","unstructured":"Wojtaszczyk A, Glajchen M, Portenoy RK, et al. Trajectories of caregiver burden in families of adult cystic fibrosis patients. Palliat Support Care. 2018;16(6):732\u201340. https:\/\/doi.org\/10.1017\/S1478951517000918.","journal-title":"Palliat Support Care"},{"key":"4514_CR32","doi-asserted-by":"publisher","first-page":"101085","DOI":"10.1016\/j.vhri.2025.101085","volume":"47","author":"T Mlcoch","year":"2025","unstructured":"Mlcoch T, Decker B, Tuzil J, et al. Life With Cystic Fibrosis: The Socioeconomic Impact on Patients and Their Caregivers. Value Health Reg Issues. 2025;47:101085. https:\/\/doi.org\/10.1016\/j.vhri.2025.101085.","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"4514_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1089\/jpm.2020.0311","volume":"24","author":"D Kavalieratos","year":"2021","unstructured":"Kavalieratos D, Georgiopoulos AM, Dhingra L, et al. Models of Palliative Care Delivery for Individuals with Cystic Fibrosis: Cystic Fibrosis Foundation Evidence-Informed Consensus Guidelines. J Palliat Med. 2021;24(1):18\u201330. https:\/\/doi.org\/10.1089\/jpm.2020.0311.","journal-title":"J Palliat Med"},{"issue":"2","key":"4514_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/children12020157","volume":"12","author":"EA Toraih","year":"2025","unstructured":"Toraih EA, Malik HA, Islam RK, et al. Clinical Outcomes in Patients with Cystic Fibrosis Receiving CFTR Modulators: A Comparison of Childhood Versus Adolescent Initiation. Children. 2025;12(2):157. https:\/\/doi.org\/10.3390\/children12020157.","journal-title":"Children"},{"issue":"1","key":"4514_CR35","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/13696998.2024.2373000","volume":"27","author":"A Lindblad","year":"2024","unstructured":"Lindblad A, Monestrol ID, Gilljam M, et al. Clinical, economic, and societal burden of cystic fibrosis and the impact of the CFTR modulator, lumacaftor\/ivacaftor: an assessment using linked registry data in Sweden. J Med Econ. 2024;27(1):897\u2013906. https:\/\/doi.org\/10.1080\/13696998.2024.2373000.","journal-title":"J Med Econ"},{"issue":"25","key":"4514_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.29057\/mjmr.v13i25.12428","volume":"13","author":"I L\u00f3pez-Hern\u00e1ndez","year":"2025","unstructured":"L\u00f3pez-Hern\u00e1ndez I. Gender perspective and determinants associated with the linkage women-informal or primary care. Mex J Med Res ICSA. 2025;13(25):15\u201322. https:\/\/doi.org\/10.29057\/mjmr.v13i25.12428.","journal-title":"Mex J Med Res ICSA"},{"key":"4514_CR37","doi-asserted-by":"publisher","first-page":"spcare","DOI":"10.1136\/spcare-2024-005015","volume":"21","author":"D Shadi","year":"2024","unstructured":"Shadi D, Jabraeili M, Hassankhani H, Alhani F, Arshadi Bostanabad M. Family caregivers of children with cystic fibrosis: supportive care needs \u2013 scoping review. BMJ Support Palliat Care Published online. October 2024;21:spcare\u20132024. https:\/\/doi.org\/10.1136\/spcare-2024-005015.","journal-title":"BMJ Support Palliat Care Published online"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04514-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04514-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04514-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:18:52Z","timestamp":1792761532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04514-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4514"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04514-z","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by a Research Ethics Committee of the International University Center UNINTER (Approval No. 7.879.811) and conducted in accordance with national and international ethical standards for research involving human subjects. All participants provided informed consent, and both respondent anonymity and data confidentiality were strictly maintained.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have provided consent for the publication of this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VDGSBO, the principal investigator of the study, has received speaking honoraria from Vertex, a company active in the field of cystic fibrosis, as well as from other pharmaceutical companies not related to the topic of this study. VBO has received honoraria from other pharmaceutical companies, also unrelated to the main topic of this study. MBM and MDM declare no conflicts of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"376"}}